Skip to main content
×
×
Home

Multiple possible inaccuracies cast doubt on a recent report suggesting selective serotonin reuptake inhibitors to be toxic and ineffective

  • Fredrik Hieronymus (a1), Alexander Lisinski (a1), Jakob Näslund (a1) and Elias Eriksson (a1)
Abstract

According to a systematic review on the use of selective serotonin reuptake inhibitors (SSRIs) in adult depression that was recently published in BMC Psychiatry, the results of which have been widely disseminated in lay media, these drugs increase the risk for serious adverse events (SAEs) while exerting poor antidepressant efficacy. A cursory analysis, however, suggests the analysis of SAEs conducted by the authors to be marred by both methodological inaccuracies and blatant errors. After having corrected for these apparent mistakes, we conducted a sensitivity analysis in which we also accounted for a possible moderating effect of age; while this suggests SSRIs to be safe drugs in the non-elderly, they do confirm what is already known, that is, that they may enhance the risk for SAEs in the old. Given the loose definition of SAE, including also innocuous phenomena, the possible clinical significance of the latter observation, however, remains unclear until the nature and actual impact of the SAEs in question have been clarified. Moreover, with respect to efficacy, we find the paper in BMC Psychiatry misleading: first, the authors seem unaware of the well-established shortcomings associated with the conventional efficacy parameter on which their analysis is based, second, they have included suboptimal SSRI doses and third, they have missed some pivotal trials. Unless there are explanations for the many peculiarities in this paper that have escaped us, and which may be satisfactorily clarified by the authors, it seems important that the conclusions presented in this paper be publicly rectified.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Multiple possible inaccuracies cast doubt on a recent report suggesting selective serotonin reuptake inhibitors to be toxic and ineffective
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Multiple possible inaccuracies cast doubt on a recent report suggesting selective serotonin reuptake inhibitors to be toxic and ineffective
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Multiple possible inaccuracies cast doubt on a recent report suggesting selective serotonin reuptake inhibitors to be toxic and ineffective
      Available formats
      ×
Copyright
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Corresponding author
Elias Eriksson, Department of Pharmacology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, POB 431, SE 405 30 Gothenburg, Sweden. Tel: +46 70 955 50 55; Fax: +46 31 82 17 95 E-mail: elias.eriksson@neuro.gu.se
References
Hide All
1. Jakobsen, JC, Katakam, KK, Schou, A et al. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMC Psychiatry. 2017;17:58.
2. Bielefeldt, AO, Danborg, PB, Gotzsche, PC. Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers. J R Soc Med 2016;109:381392.
3. Schneider, LS, Nelson, JC, Clary, CM et al. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 2003;160:12771285.
4. Kasper, S, De Swart, H, Friis Andersen, H. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry 2005;13:884891.
5. Lundbeck. Clinical trial report summary – study 99024, 2005. Available at http://www.lundbeck.com/upload/trials/files/pdf/completed/99024_CTRS_final_30Dec2005.pdf.
6. Kranzler, HR, Mueller, T, Cornelius, J et al. Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol 2006;26:1320.
7. Lundbeck. Clinical trial report summary – study 99003, 2005. Available at http://www.lundbeck.com/upload/trials/files/pdf/completed/99003_CTRS_final_30Dec2005.pdf.
8. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John’s wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002;287:18071814.
9. Astrazeneca. ClinicalTrials.gov study results – NCT01020799, 2012. Available at https://clinicaltrials.gov/ct2/show/results/NCT01020799.
10. Glaxosmithkline. Scientific result summary – PAR 29060.02.001, 2008. Available at https://www.gsk-clinicalstudyregister.com/files2/1860.pdf.
11. Glaxosmithkline. Scientific result summary – PAR 29060.03.003, 2008. Available at https://www.gsk-clinicalstudyregister.com/files2/1876.pdf.
12. Glaxosmithkline. Scientific result summary – PAR 29060.03.001, 2008. Available at https://www.gsk-clinicalstudyregister.com/files2/2780.pdf.
13. Glaxosmithkline. Scientific result summary – 29060.487, 2005. Available at https://www.gsk-clinicalstudyregister.com/files2/2063.pdf.
14. Glaxosmithkline. Scientific result summary – 29060.625, 2005. Available at https://www.gsk-clinicalstudyregister.com/files2/1910.pdf.
15. Glaxosmithkline. Scientific result summary – WELL AK1A4006, 2005. Available at https://www.gsk-clinicalstudyregister.com/files2/820.pdf.
16. Glaxosmithkline. Scientific result summary – WELL AK1A4007, 2005. Available at https://www.gsk-clinicalstudyregister.com/files2/821.pdf.
17. Glaxosmithkline. Clinical study register. Available at https://www.gsk-clinicalstudyregister.com/.
18. Sweeting, MJ, Sutton, AJ, Lambert, PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:13511375.
19. Friedrich, JO, Adhikari, NK, Beyene, J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol 2007;7:5.
20. Pettinati, HM, Oslin, DW, Kampman, KM et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry 2010;167:668675.
21. Ravindran, AV, Teehan, MD, Bakish, D et al. The impact of sertraline, desipramine, and placebo on psychomotor functioning in depression. Hum Psychopharmacol. 1995;10:273281.
22. De Vries, YA, Roest, AM, Beijers, L, Turner, EH, De Jonge, P. Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: a meta-analysis. Eur Neuropsychopharmacol. 2016;26:17521759.
23. Ioannidis, JP. Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch Intern Med 2009;169:17371739.
24. Aftonbladet. Dansk studie sågar antidepressiva mediciner (in Swedish), 2017. Available at http://www.aftonbladet.se/senastenytt/ttnyheter/utrikes/article24393582.ab.
25. Sciencenordic. Do antidepressants do more harm than good?, 2017. Available at http://sciencenordic.com/do-antidepressants-do-more-harm-good.
26. DANISH TV2. Interview with Janus Christian Jakobsen, 2017. Available at https://www.youtube.com/watch?v=XRJevSWYE2o.
27. Ball, WA, Snavely, DB, Hargreaves, RJ, Szegedi, A, Lines, C, Reines, SA. Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder. Hum Psychopharmacol. 2014;29:568577.
28. Nyth, AL, Gottfries, CG, Lyby, K et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992;86:138145.
29. Glaxosmithkline. Scientific result summary – 29060.810, 2005. Available at https://www.gsk-clinicalstudyregister.com/files2/2204.pdf.
30. Mathews, M, Gommoll, C, Chen, D, Nunez, R, Khan, A. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 2015;30:6774.
31. Forest Laboratories. ClinicalTrials.gov – NCT01473381, 2014. Available at https://clinicaltrials.gov/ct2/show/results/NCT01473381.
32. Glaxosmithkline. Scientific result summary – 29060.785, 2005. Available at https://www.gsk-clinicalstudyregister.com/files2/2202.pdf.
33. US Food and Drug Administration, Center for Drug Evaluation and Research. Statistical review – Lexapro NDA 021323, 2001. Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Statr.pdf.
34. Higgins, JPT, Green, S. Cochrane handbook for systematic reviews of interventions version 5.1.0, 16.5.4, 2011. Available at http://handbook-5-1.cochrane.org/chapter_16/16_5_4_how_to_include_multiple_groups_from_one_study.htm.
35. Feighner, JP, Overo, K. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry 1999;60:824830.
36. Groenwold, RH, Rovers, MM, Lubsen, J, Van Der Heijden, g. Subgroup effects despite homogeneous heterogeneity test results. BMC Med Res Methodol 2010;10:43.
37. Loo, H, Hale, A, D’haenen, H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002;17:239247.
38. Lundbeck. Clinical trial report summary – study 99001, 2005. Available at http://www.lundbeck.com/upload/trials/files/pdf/completed/99001_CTRS_final_30Dec2005.pdf.
39. US Food and Drug Administration, Center for Drug Evaluation and Research. Celexa label, 2012. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020822s042,021046s019lbl.pdf.
40. Medicines and Healthcare Products Regulatory Agency. Package leaflet – information for the user (Citalopram), 2016. Available at http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1466141077922.pdf.
41. Ostergaard, SD. Do not blame the SSRIs: blame the Hamilton Depression Rating Scale. Acta Neuropsychiatr. 2017:13.
42. Wernicke, JF, Dunlop, SR, Dornseif, BE, Zerbe, RL. Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull. 1987;23:164168.
43. Wernicke, JF, Dunlop, SR, Dornseif, BE, Bosomworth, JC, Humbert, M. Low-dose fluoxetine therapy for depression. Psychopharmacol Bull. 1988;24:183188.
44. Mendels, J, Kiev, A, Fabre, LF. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depress Anxiety. 1999;9:5460.
45. Glaxosmithkline. Scientific result summary – PAR 29060.02.002, 2008. Available at https://www.gsk-clinicalstudyregister.com/files2/1861.pdf.
46. Glaxosmithkline. Scientific result summary – PAR 29060.02.003, 2008. Available at https://www.gsk-clinicalstudyregister.com/files2/1862.pdf.
47. Glaxosmithkline. Scientific result summary – PAR 29060.02.004, 2008. Available at https://www.gsk-clinicalstudyregister.com/files2/2820.pdf.
48. Glaxosmithkline. Scientific report summary – PAR 29060.03.002, 2008. Available at https://www.gsk-clinicalstudyregister.com/files2/1875.pdf.
49. Glaxosmithkline. Scientific result summary – PAR 29060.03.004, 2008. Available at https://www.gsk-clinicalstudyregister.com/files2/1877.pdf.
50. Glaxosmithkline. Scientific result summary – PAR 29060.03.005, 2008. Available at https://www.gsk-clinicalstudyregister.com/files2/1878.pdf.
51. US Food and Drug Administration, Center for Drug Evaluation and Research. Paxil NDA 020031 approval letter, statistical review, 1992.
52. US Food and Drug Administration, Center for Drug Evaluation and Research. Celexa NDA 20-822 approval letter, medical review (part 5), 1998. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020822a_medr_P5.pdf.
53. Fabre, LF. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. J Clin Psychiatry 1992;53(Suppl):4043.
54. Glaxosmithkline. Scientific result summary – PAR 29060.03.006, 2008. Available at https://www.gsk-clinicalstudyregister.com/files2/1879.pdf.
55. Hieronymus, F, Nilsson, S, Eriksson, E. A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. Transl Psychiatry. 2016;6:e834.
56. Hieronymus, F, Emilsson, JF, Nilsson, S, Eriksson, E. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol Psychiatry. 2016;21:523530.
57. Bech, P. Is the antidepressant effect of second-generation antidepressants a myth? Psyhcological Medicine 2010;40:181186.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Acta Neuropsychiatrica
  • ISSN: 0924-2708
  • EISSN: 1601-5215
  • URL: /core/journals/acta-neuropsychiatrica
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Type Description Title
UNKNOWN
Supplementary materials

Hieronymus supplementary material
Hieronymus supplementary material 1

 Unknown (27 KB)
27 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed